The Welland Tribune

Pariah ex-CEO ignores lawyers, won’t keep mouth shut

-

TOM HAYS

NEW YORK — “Pharma Bro” just won’t keep his mouth shut.

Even before his federal securities fraud trial began Monday, Martin Shkreli blatantly defied his attorneys’ advice to lay low. The former pharmaceut­ical CEO, who became a pariah after raising the cost of a life-saving drug 5,000 per cent, has been preening for cameras and trolling on social media, potentiall­y complicati­ng his defence.

“I’m excited,” Shkreli said of the trial in a brief phone call last week. “I can’t wait.”

Jury selection got underway Monday, and opening statements could occur as early as Tuesday.

Since his high-profile arrest in late 2015 when he was led into court in a grey hoodie, Shkreli has been free on bail and free to speak his mind. He went on Twitter to label members of Congress “imbeciles” for demanding to know why his company, Turing Pharmaceut­icals, raised the price of Daraprim, a drug used to treat toxoplasmo­sis and HIV, from $13.50 to $750 per pill.

He took to YouTube for a series of lessons on chemistry and stock market analysis. His Twitter posts mocking a freelance journalist turned so creepy — one showed a fake photo of him canoodling with her — that his account was shut down. And on Facebook, he mused about the possibilit­y of being “unjustly imprisoned.”

The 34-year-old Shkreli “travels to the beat of a very unique drummer,” exasperate­d-sounding defence attorney Benjamin Brafman said at a pretrial hearing this month.

Legal experts say there are obvious reasons lawyers want clients facing serious criminal charges to keep quiet.

“It’s twofold: You don’t want to antagonize the judge and you don’t want to get the attention of the jury in a way that hurts your case,” said veteran New York City defence attorney Gerald Lefcourt.

Though Shkreli’s notoriety came from Daraprim, the federal securities fraud case is unrelated. Prosecutor­s say that after Shkreli lost millions of dollars through bad trades through his side business hedge fund, he looted a second pharmaceut­ical company for $11 million to pay them back. The defence has argued that he had good intentions.

“Everybody got paid back in this case,” his lawyer said. “Whatever else he did wrong, he ultimately made them whole.”

The defence has floated the possibilit­y that it would put Shkreli on the witness stand to try to highlight how he grew up in a workingcla­ss Albanian family in Brooklyn, taught himself chemistry, interned at a financial firm founded by CNBC’s Jim Cramer and struck out on his own to become a rising star in biotechnol­ogy startups. He wanted to develop new life-saving drugs after seeing “several classmates and other children he knew struck down by debilitati­ng disease,” court papers say.

Prosecutor­s call it a ploy to portray the boyish-looking Shkreli as “a Horatio Alger-like figure who, through hard work and intelligen­ce, is in a position to do great things if only the jury would ignore the evidence and base its verdict on sympathy.” The real Shkreli was a con man often undone by his own mouth, they say.

The government has cited claims by one of Shkreli’s former employees that Shkreli harassed his family in a dispute over shares of stock.

“I hope to see you and your four children homeless and will do whatever I can to assure this,” Shkreli wrote the employee’s wife, according to court filings.

Prosecutor­s also used his boasts about some of his purchases of eccentric collectibl­es to undermine efforts to reduce his bail from $5 million to $2 million. If he needed to raise cash to pay legal fees and back taxes, they argued, why not sell the one-ofa-kind Wu-Tang Clan album that he brought for $2 million or his Nazi-era Engima code-breaking machine?

Also cited were his offers to pay a $100,000 bounty for finding the killer of a Democratic National Committee staffer and $40,000 in tuition for a Princeton student who solved a math problem he posed during a guest lecture at the school earlier this year.

Shkreli “is not the demon he’s been made out to be,” the student, Yuan Wang, said.

Still, he added, “I haven’t received the money yet.”

 ?? SETH WENIG/THE ASSOCIATED PRESS ?? Former Turing Pharmaceut­icals CEO Martin Shkreli, left, arrives at court with his lawyer Benjamin Brafman, in New York on Monday. Shkreli is on trial for securities fraud.
SETH WENIG/THE ASSOCIATED PRESS Former Turing Pharmaceut­icals CEO Martin Shkreli, left, arrives at court with his lawyer Benjamin Brafman, in New York on Monday. Shkreli is on trial for securities fraud.

Newspapers in English

Newspapers from Canada